2025年6月10日 周二
Home > Archive>Volume 32, Issue 4, 2024 >347-354
PDF HTML XML Export Cite reminder
Differences in the diagnosis and treatment guidelines at home and abroad for non-alcoholic fatty liver disease and treatment prospects
Author:
Affiliation:

College of Pharmacy, Naval Medical University, Shanghai 200433, China)

Clc Number:

R5

  • Article
    • | |
  • Metrics
    • |
  • Reference [38]
    • |
  • Related [20]
    • | | |
  • Comments
    Abstract:

    Non-alcoholic fatty liver disease (NAFLD), a metabolic stress-induced liver injury, is characterized by excessive accumulation of fat in the liver, which is closely related to insulin resistance and genetic susceptibility. It is estimated that 25% of the world's population are currently diagnosed with NAFLD, which has a huge impact on socioeconomic development and people's health. The prevalence of NAFLD in different countries/regions is different based on the living customs and population genetic differences in different regions, and there are also certain differences in the diagnostic criteria and treatment plans of NAFLD in the recommendations given by the national/regional diagnosis and treatment guidelines. This article aims to compare the latest domestic and international guidelines on the diagnosis and treatment of NAFLD, as well as summarise the latest research advances in the treatment of NAFLD, in order to provide recommendations for the clinical management of NAFLD.

    Reference
    [1] ESLAM M, SANYAL A J, GEORGE J, et al.MAFLD:a consensus-driven proposed nomenclature for metabolic associated fatty liver disease.Gastroenterology, 0,8(7):1999-2014.
    [2] GOFTON C, UPENDRAN Y, ZHENG M H, et al.MAFLD:how is it different from NAFLD?.Clin Mol Hepatol, 3,9(Suppl):S17-S31.
    [3] RIAZI K, AZHARI H, CHARETTE J H, et al.The prevalence and incidence of NAFLD worldwide:a systematic review and Meta-analysis.Lancet Gastroenterol Hepatol, 2,7(9):851-861.
    [4] YIP T C F, LEE H W, CHAN W K, et al.Asian perspective on NAFLD-associated HCC.J Hepatol, 2,6(3):726-734.
    [5] ESTES C, ANSTEE Q M, ARIAS-LOSTE M T, et al.Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.J Hepatol, 8,9(4):896-904.
    [6] IM P K, YANG L, KARTSONAKI C, et al.Alcohol metabolism genes and risks of site-specific cancers in Chinese adults:an 11-year prospective study.Int J Cancer, 2,0(10):1627-1639.
    [7] CHALASANI N, YOUNOSSI Z, LAVINE J E, et al.The diagnosis and management of nonalcoholic fatty liver disease:practice guidance from the American Association for the Study of Liver Diseases.Hepatology, 8,7(1):328-357.
    [8] European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO).EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease.Obes Facts, 6,9(2):65-90.
    [9] Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell'Obesità (SIO), Members of the guidelines panel, et al.Non-alcoholic fatty liver disease in adults 2021:a clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).Nutr Metab Cardiovasc Dis, 2,2(1):1-16.
    [10] KANG S H, LEE H W, YOO J J, et al.KASL clinical practice guidelines:management of nonalcoholic fatty liver disease.Clin Mol Hepatol, 1,7(3):363-401.
    [11] TOKUSHIGE K, IKEJIMA K, ONO M, et al.Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.J Gastroenterol, 1,6(11):951-963.
    [12] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018更新版).传染病信息, 8,1(5):393-2,0.Fatty Liver and Alcoholic Liver Disease Group of the Hepatology Branch of the Chinese Medical Association, Expert Committee on Fatty Liver Disease of the Chinese Medical Association.Guidelines of prevention and treatment for nonalcoholic fatty liver disease:a 2018 update.Infect Dis Inf, 8,1(5):393-2,0.
    [13] KLEINER D E, BRUNT E M, VAN NATTA M, et al.Design and validation of a histological scoring system for nonalcoholic fatty liver disease.Hepatology, 5,1(6):1313-1321.
    [14] Bedossa P, FLIP Pathology Consortium.Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease.Hepatology, 4,0(2):565-575.
    [15] BEDOSSA P, POITOU C, VEYRIE N, et al.Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.Hepatology, 2,6(5):1751-1759.
    [16] 中华医学会内分泌学分会.非酒精性脂肪性肝病与相关代谢紊乱诊疗共识(第二版).中华内分泌代谢杂志, 8,4(7):549-554.Endocrinology Branch of the Chinese Medical Association.Consensus on the diagnosis and treatment of non-alcoholic fatty liver disease and related metabolic disorders (second edition).Chin J Endocrinol Metab, 8,4(7):549-554.
    [17] 中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会, 中华医学会肝病学分会脂肪肝与酒精性肝病学组, 等.中国脂肪性肝病诊疗规范化的专家建议(2019年修订版).现代医药卫生, 9,5(23):3728-3732.Liver Disease Professional Committee of China Research Hospital Association, Expert Committee on Fatty Liver Disease of the Chinese Medical Association, Fatty Liver and Alcoholic Liver Disease Group of the Hepatology Branch of the Chinese Medical Association, et al.Expert recommendations for the diagnosis and management of fatty liver diseases in China (update 2019).J Mod Med Health, 9,5(23):3728-3732.
    [18] IMAJO K, KESSOKU T, HONDA Y, et al.Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography.Gastroenterology, 6,0(3):626-637.
    [19] WONG V W S, CHAN W K, CHITTURI S, et al.Asia-pacific working party on non-alcoholic fatty liver disease guidelines 2017-part 1:definition, risk factors and assessment.J Gastroenterol Hepatol, 8,3(1):70-85.
    [20] MUSSO G, CASSADER M, ROSINA F, et al.Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD):a systematic review and Meta-analysis of randomised trials.Diabetologia, 2,5(4):885-904.
    [21] UTZ-MELERE M, TARGA-FERREIRA C, LESSA-HORTA B, et al.Non-alcoholic fatty liver disease in children and adolescents:lifestyle change-a systematic review and Meta-analysis.Ann Hepatol, 8,7(3):345-354.
    [22] 中华中医药学会脾胃病分会.非酒精性脂肪性肝病中医诊疗指南(基层医生版).中西医结合肝病杂志, 9,9(5):483-486.Spleen and Stomach Disease Branch of the Chinese Association of Traditional Chinese Medicine.Guidelines for diagnosis and treatment of nonalcoholic fatty liver disease in traditional Chinese medicine (grassroots doctor edition).Chin J Integr Tradit Western Med Liver Dis, 9,9(5):483-486.
    [23] PLAUTH M, BERNAL W, DASARATHY S, et al.ESPEN guideline on clinical nutrition in liver disease.Clin Nutr, 9,8(2):485-521.
    [24] BISCHOFF S C, BERNAL W, DASARATHY S, et al.ESPEN practical guideline:clinical nutrition in liver disease.Clin Nutr, 0,9(12):3533-3562.
    [25] ESLAM M, SARIN S K, WONG V W S, et al.The Asian pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.Hepatol Int, 0,4(6):889-919.
    [26] BRIL F, KALAVALAPALLI S, CLARK V C, et al.Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes.Clin Gastroenterol Hepatol, 8,6(4):558-566.
    [27] KALAVALAPALLI S, BRIL F, KOELMEL J P, et al.Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis.Am J Physiol Endocrinol Metab, 8,5(2):E163-E173.
    [28] SANYAL A J, CHALASANI N, KOWDLEY K V, et al.Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.N Engl J Med, 0,2(18):1675-1685.
    [29] MAHADY S E, WEBSTER A C, WALKER S, et al.The role of thiazolidinediones in non-alcoholic steatohepatitis-a systematic review and Meta analysis.J Hepatol, 1,5(6):1383-1390.
    [30] LIN H Z, YANG S Q, CHUCKAREE C, et al.Metformin reverses fatty liver disease in obese, leptin-deficient mice.Nat Med, 0,6(9):998-1003.
    [31] LI Y, LIU L, WANG B, et al.Metformin in non-alcoholic fatty liver disease:a systematic review and Meta-analysis.Biomed Rep, 3,1(1):57-64.
    [32] MUSSO G, GAMBINO R, CASSADER M, et al.A Meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease.Hepatology, 0,2(1):79-104.
    [33] LOOMBA R, ABDELMALEK M F, ARMSTRONG M J, et al.Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis:a randomised, placebo-controlled phase 2 trial.Lancet Gastroenterol Hepatol, 3,8(6):511-522.
    [34] 陈梦绮, 范建高.非酒精性脂肪性肝病相关心血管疾病的发病机制.中国动脉硬化杂志, 3,1(6):461-465.CHEN M Q, FAN J G.Pathogenesis of cardiovascular disease associated with nonalcoholic fatty liver disease.Chin J Arterioscler, 3,1(6):461-465.
    [35] RATZIU V, DE LEDINGHEN V, OBERTI F, et al.A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.J Hepatol, 1,4(5):1011-1019.
    [36] LEUSCHNER U F H, LINDENTHAL B, HERRMANN G, et al.High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis:a double-blind, randomized, placebo-controlled trial.Hepatology, 0,2(2):472-479.
    [37] LINDOR K D, KOWDLEY K V, HEATHCOTE E J, et al.Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis:results of a randomized trial.Hepatology, 4,9(3):770-778.
    [38] PAIS R, BARRITT A S 4TH, CALMUS Y, et al.NAFLD and liver transplantation:current burden and expected challenges.J Hepatol, 6,5(6):1245-1257.
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

LI Xiang, CHEN Yi, LIU Xia, SUN Yang. Differences in the diagnosis and treatment guidelines at home and abroad for non-alcoholic fatty liver disease and treatment prospects[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2024,32(4):347-354.

Copy
Share
Article Metrics
  • Abstract:209
  • PDF: 699
  • HTML: 0
  • Cited by: 0
History
  • Received:May 03,2023
  • Revised:July 08,2023
  • Online: April 29,2024
Article QR Code

You are the 57247 visitor

Post Code：421001 Fax：0734-8160523

Phone：0734-8160765 E-mail：dmzzbjb@163.net

Editorial Office of Chinese Journal of Arteriosclerosis ® 2025